A Phase 3 Study in Moderate to Severe Psoriasis Patients
- Registry ID
- EUCTR2011-004368-31
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Eli Lilly and Company
- Start date
- 2012-09-13
- Completion date
- 2019-07-22
- Last update
- 2026-08-16
Conditions
- Moderate to severe plaque psoriasis
Summary
Efficacy of ixekizumab vs. etanercept and placebo in subjects with moderate to severe chronic plaque psoriasis based on sPGA and PASI at week 12
Locations
- , , Poland
- , , Germany
- , , Bulgarian Drug Agency
- , , Hungary
View on source registry